PARP Inhibitors for Ovarian Cancer

The combination of pembrolizumab and lenvatinib led to encouraging clinical activity in patients with platinum-resistant high-grade serous ovarian cancer.

In season 2, episode 6 of Targeted Talks, Alexander B. Olawaiye, MD leads a discussion with Haider S. Mahdi, MD, about the modern approaches to treating cervical and endometrial cancers.

Stuart J. Schnitt, MD, discussed how AI enhances cancer diagnoses and the need for professional oversight, ethical clarity, and equitable adoption.

Sarah M. Temkin, MD leads discussion with Daphne B. Stewart, MD, around targeted therapies in ovarian cancer, whether offered in the academic or community setting.

Christopher Schenewerk, MD, discussed his history with alcohol abuse and how he works to break down the taboo of substance abuse among medical professionals.